Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Lucanix™ (TGF-beta2 Antisense Gene Modified Allogeneic Tumor Cell Vaccine) in Patients With Stages II-IV Non-Small Cell Lung Cancer

NCT01058785 is registered in ClinicalTrials.gov with NovaRx Corporation as lead sponsor.

NCT NCT01058785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01058785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Lucanix™ (TGF-beta2 Antisense Gene Modified Allogeneic Tumor Cell Vaccine) in Patients With Stages II-IV Non-Small Cell Lung Cancer
Lead sponsor
NovaRx Corporation
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2003
Completion date
December 31, 2005
Enrollment
75 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, bronchogenic, lung neoplasm